Skip to main content
ANAB
NASDAQ Life Sciences

Anaptys Posts $177M Q2 Profit on Jemperli Royalties, Flags Key FDA Decisions

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$55.99
Mkt Cap
$1.626B
52W Low
$13.658
52W High
$72.36
52W Position info
310% above low
Off High info
23% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ANAB has more than doubled off its 52-week low of $13.658.

Summary

AnaptysBio reported Q2 2026 net income from continuing operations of $177.3 million, driven by a $181.5 million tax benefit from releasing a valuation allowance. Collaboration revenue rose to $27.5 million, up from $22.3 million a year ago, as Jemperli royalties grew 25% year-over-year. GSK's Jemperli hit $331 million in Q2 global sales, up 26%, and the company reiterated expectations for over $390 million in annualized royalties by 2029. Key upcoming catalysts include an FDA decision on Jemperli in rectal cancer (PDUFA February 2027), a Quimilza approval decision in GPP (December 12, 2026), and a post-trial hearing in the GSK/Tesaro litigation on October 20, 2026. Cash stood at $164.1 million as of June 30, 2026, down from $211.6 million at year-end 2025, with no shares repurchased under the $100 million buyback plan. The company completed its spin-off of First Tracks Biotherapeutics in April 2026 and changed its fiscal year-end to June 30.

At the time of this announcement, ANAB was trading at $55.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $13.66 to $72.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ANAB - Latest Insights

ANAB
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $47.77 info
Change: $0 (0%) info
Market Cap: $1.428B info
ANAB
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $47.77 info
Change: $0 (0%) info
Market Cap: $1.428B info
ANAB
Oct 20, 2026, 3:49 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $45.00
Real-time Price: $47.77 info
Change: +$2.77 (+6%) info
Market Cap: $1.428B info
ANAB
Oct 19, 2026, 2:18 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $49.23
Real-time Price: $47.77 info
Change: -$1.46 (-3%) info
Market Cap: $1.428B info
ANAB
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $50.85
Real-time Price: $47.77 info
Change: -$3.08 (-6%) info
Market Cap: $1.428B info